STOCK TITAN

Coeptis Therapeutics Holdings, Inc. - $COEP STOCK NEWS

Welcome to our dedicated page for Coeptis Therapeutics Holdings news (Ticker: $COEP), a resource for investors and traders seeking the latest updates and insights on Coeptis Therapeutics Holdings stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Coeptis Therapeutics Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Coeptis Therapeutics Holdings's position in the market.

Rhea-AI Summary

Coeptis Therapeutics Holdings, a biopharmaceutical company, will present its innovative universal allogeneic SNAP-CAR NK cell therapy at the ISCT 2024 conference. This therapy has the potential to target multiple antigens, potentially avoiding toxicities and relapse. Coeptis expanded its license agreement for SNAP-CAR to include natural killer cells, aiming to develop a safer and cost-effective cellular therapy. The company's presentation at ISCT 2024 signifies a significant step towards universalizing the treatment of various diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.2%
Tags
conferences
-
Rhea-AI Summary

Coeptis Therapeutics Holdings, a biopharmaceutical company, will present data on the development of SNAP-CAR NK cells at the ASGCT Annual Meeting. The Company aims to revolutionize cancer treatment with a universal targeted cell therapy that eliminates the need for HLA matching.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.77%
Tags
none
-
Rhea-AI Summary
Coeptis Therapeutics congratulates Professor Deiters for receiving the University of Pittsburgh's 2024 Chancellor's Distinguished Research Award for his innovative CAR T cell therapy platform. The company aims to revolutionize oncology and autoimmune disorder treatments with SNAP-CAR technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.78%
Tags
none
Rhea-AI Summary
Coeptis Therapeutics Holdings, Inc. expands its exclusive license agreement with the University of Pittsburgh to include autoimmune indications for its SNAP-CAR T and SNAP-CAR NK cell therapy platforms. The technology has the potential to target multiple antigens simultaneously, impacting autoimmune diseases and oncology indications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.98%
Tags
none
-
Rhea-AI Summary
Coeptis Therapeutics Holdings, Inc. announces plans to pursue DVX201, a novel allogeneic stem cell expansion and directed differentiation platform of unmodified natural killer (NK) cell therapy, as an antiviral treatment for severe respiratory viral infections, including influenza, COVID-19, and respiratory syncytial virus (RSV). The therapy aims to replenish immune cells to help fight the infection and has shown promising results in Phase 1 clinical trials for patients with COVID-19 and hematological malignancies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.57%
Tags
-
Rhea-AI Summary
Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) announced President and CEO Dave Mehalick's Letter to Shareholders, detailing the exclusive licensing agreement with Deverra Therapeutics Inc, the progress of DVX201 allogeneic NK cell therapy, and the company's vision for developing next-generation cell therapy technologies for cancer and infectious diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.65%
Tags
none
Rhea-AI Summary
Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) announced that Dave Mehalick, President and CEO, will deliver a virtual presentation at the Emerging Growth Conference on December 6th, 2023. Coeptis is a biopharmaceutical company developing innovative cell therapy platforms for cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.35%
Tags
conferences acquisition
-
Rhea-AI Summary
Coeptis Therapeutics announces research demonstrating the potential of the SNAP-CAR T-cell platform to target multiple antigens through combinatorial use of different adaptors. The research shows versatile antigen targeting abilities in vitro and in vivo, including potent and specific function, tumor reduction, and inhibition of tumor growth. The findings suggest the SNAP-CAR platform has vast potential for treating various cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.74%
Tags
none
-
Rhea-AI Summary
Coeptis Therapeutics Holdings, Inc. has entered into a definitive agreement for a private placement of 2,000,000 shares of its common stock, with expected gross proceeds of $2,000,000. The company intends to use the net proceeds for working capital and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.41%
Tags
none
Rhea-AI Summary
Coeptis expands exclusive license agreement with University of Pittsburgh for SNAP-CAR technology platform in NK cells. Also obtains exclusive rights to negotiate acquisition of GEAR™ cell therapy and companion diagnostic platforms from VyGen Bio.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.61%
Tags
none
Coeptis Therapeutics Holdings, Inc.

Nasdaq:COEP

COEP Rankings

COEP Stock Data

9.87M
20.21M
32.54%
13.11%
0.3%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
WEXFORD